background: Cumulus cell (CC) gene expression is suggested as a non-invasive analysis method to predict oocyte competence. There are, however, important between-patient differences in CC gene expression. These can be compensated when expression results are combined with patient and cycle characteristics using a multiple regression analysis model.
Introduction
Several authors propose the use of cumulus cell (CC) gene expression as a non-invasive analysis method in human assisted reproductive technology (ART) to predict oocyte competence (McKenzie et al., 2004; Feuerstein et al., 2007; Assou et al., 2008; van Montfoort et al., 2008) . Evaluation methods predictive for fertilization, embryo and blastocyst development and ideally also pregnancy are needed in view of a more effective single embryo transfer (SET) policy. Table I gives an overview of recent literature dealing with human cumulus or granulosa cell gene expression and oocyte competence. Several genes were reported to be up-or down-regulated in the cumulus of competent oocytes but data suggest that a combination of genes will be required to make more accurate predictions. Depending on the considered end-point, the predictive power of a gene changes, e.g. prostaglandin-endoperoxide synthase 2 (PTGS2) expression was positively related to nuclear maturation, but not predictive for embryo morphology on Day 2 and inversely correlated to † Both authors contributed equally to this work and share first authorship. the ability to develop up to Day 5 or 6 (Feuerstein et al., 2007) . The between-patient variation in gene expression is considerable and this variation is related to treatment-cycle-related variables such as the type of gonadotrophin preparation used . The use of a multivariate analysis combines variables that might help us to increase the predictive power. Using stepwise multivariate regression analysis, response variables such as blastocyst development or pregnancy are written as a function of the expression values of the most predictive genes and if necessary corrected for significant cycle and patient dependent variables such as age, serum FSH levels, ovarian response or treatment regime of the patient . Eight genes (Table II) , which are differentially expressed in CC in relation to oocyte competence (own unpublished microarray analysis data), were analyzed with quantitative PCR (QPCR) in ICSI patients. The functional annotation indicated that the genes analyzed are involved in cell movement, cell adhesion and cell differentiation, all pointing towards the expansion and mucification process occurring in the CC.
An earlier publication demonstrated the presence and differential expression of Syndecan 4 (SDC4), Versican (VCAN), PTGS2, activated leukocyte cell adhesion molecule (ALCAM) and Gremlin 1 (GREM1) during the ovulatory response in mouse and human CC (Adriaenssens et al., , 2011 and also depicts the possible interrelation.
A protein-protein interaction prediction analysis (http://www. compbio.dundee.ac.uk/www-pips) confirmed that Calmodulin 2 (CALM2) is downstream of the epidermal growth factor (EGF) and EGF-like family members (Erag, Areag and Betacellulin) signaling, with high total interaction scores for the ERBB2-4 (v-erb-b2 erythroblastic leukemia viral oncogene receptors) of respectively 7.8, 11.6 and 21.6. CALM2 also interacts with Inositol 1,4,5-trisphosphate 3-kinase A (ITPKA) (10.9). For the transient receptor potential cation channel, subfamily M, member 7 (TRPM7) regulation by EGF, LH or hCG is not described. The exact functions of the three calcium-pathway-related genes in the CC still need to be determined.
Relevant clinical and treatment cycle related biochemical parameters of the patients were recorded. The response variables considered were nuclear development, fertilization, fragmentation, developmental speed and the resulting embryo score on Day 3 and Day 5 of culture.
The first aim of the study was to estimate the between-and withinpatient variation for the considered genes. The within-patient variation in CC gene expression was then related to nuclear maturity of the oocyte. Finally, a multivariate regression analysis allowing corrections for between-patient variations determined the predictive power, if any, of metaphase II (MII) oocyte CC gene expression analysis in relation to good cleavage-stage embryo or blastocyst quality and pregnancy in ICSI cycles after the two most common stimulation protocols. CC gene expression and oocyte competence was idiopathic for 10%, male factor only for 55%, combined male and female factor for 19% (polycystic ovary 3%, tubal 6% and endometriosis 10%) and female factor only for 16% (endometriosis). There were 11 antagonist/rFSH-stimulated patients who became pregnant following a SET on Day 3 (n ¼ 4) or on Day 5 (n ¼ 7) as detected by fetal heartbeat in week 7 or 8 after transfer, and 10 delivered a healthy child (there was one early miscarriage at Week 12). There were 14 patients with similar characteristics and ovarian stimulation treatment, who were not pregnant after receiving a good quality embryo after SET on Day 3 (n ¼ 6) or Day 5 (n ¼ 8). From the 20 agonist/ HP-hMG-stimulated patients, 18 had an embryo transfer at Day 3 and 2 at Day 5. There were nine patients who became pregnant, as detected by fetal heartbeat in Week 7 or 8, eight after SET and one from a dizygotic twin after double embryo transfer (DET); all but one patient (who had a stillbirth in Week 21) delivered live borns. There were 11 agonist/ HP-hMG-stimulated patients who were not pregnant after SET (n ¼ 9) or DET (n ¼ 2). Only CC of SET patients were used for pregnancy prediction.
Materials and Methods

Patient population
Collection of human CCs
Cumulus -oocyte complexes (COCs) were retrieved 36 h post hCG. COCs were collected and washed in multiple dishes with HEPES buffered human tubal fluid (HTF, Lonza, Verviers, Belgium) supplemented with serum substitute supplement (SSS, Irvine Scientific, Santa Ana, CA, USA) in order to remove loose cells, blood, cell debris and large (mural) cell clumps. COCs were incubated in fertilization medium covered with paraffin oil (Irvine Scientific) until denudation. Shortly before ICSI, oocytes were denuded individually in a 40 ml droplet of HTF-SSS containing 40 IU/ml hyaluronidase (Type VIII, Sigma Chemical Company, St Louis, MO, USA) for a maximum of 30 s and washed sequentially in two droplets without enzyme. The CC of individual oocytes were snap frozen by plunging in liquid nitrogen immediately after denudation, and MII oocytes were used for ICSI. Oocytes were individually fertilized and embryos were individually cultured. The embryo transferred was recorded and allowed retrospective analysis of the CC. All manipulations were performed under sterile conditions on heatedstage microscopes (378C).
Outcome parameters considered for oocyte developmental competence
Patient characteristics and ovarian stimulation dependent variables are enumerated in Table III . Outcome parameters related to oocyte developmental competence were: (i) fertilization on Day 1 post-insemination (fertilization or 2PN); (ii) developmental speed, i.e. ≥7 cells or ,7 cells embryo stage (≥7 cells on Day 3); (iii) degree of fragmentation on Day 3, i.e. ≤10% fragmentation or .10% fragmentation (fragmentation ≤10% on Day 3); (iv) the best embryo quality on Day 3, i.e. embryo quality 1 ¼ ≥7 blastomeres with ≤10% fragmentation (Staessen et al., 1994 ) (embryo quality 1); (v) embryo quality ≤2 on Day 3, i.e. embryo score 1 or 2 with score 2 ¼ ≥7 blastomeres with ≤20% fragmentation (embryo quality ≤2 on Day 3); (vi) the best blastocyst quality on Day 5, i.e. blastocyst score 1 ¼ BL 3 -5, AA or AB (inner cell mass/trophectoderm (ICM/TE) with ≤10% fragmentation (Gardner and Schoolcraft, 1999 ) (blastocyst quality 1); (vii) good blastocyst quality on Day 5, blastocyst score 1 or 2 with score 2 ¼ BL 1, 2 or BL 3 -5 with BA or BB (ICM/ TE score) with ≤20% fragmentation (blastocyst quality ≤2 on Day 5).
From five antagonist/rFSH and seven agonist/HP-hMG-stimulated patients, not only the CC derived from mature (MII) oocyte (n ¼ 28 and n ¼ 51, respectively), but also those from germinal vesicle (GV; n ¼ 10 and n ¼ 13), and metaphase I (MI; n ¼ 6 and n ¼ 12) oocytes were Figure 1 The patient population. From 45 ICSI patients, cumulus-oocyte complexes (COCs) were individually denuded, fertilized, cultured and the cumulus cells (CCs) were frozen. Twenty-five patients were stimulated with GnRH antagonist and recombinant FSH (rFSH) and 20 with GnRH agonist and HP hMG. (A) The gene expression in CCs of mature MII oocytes and immature GV and MI oocytes, was compared using a paired t-test in GnRH antagonist and recombinant FSH (rFSH) (n ¼ 5) and GnRH agonist and HP hMG-stimulated patients (n ¼ 7). (B) A multivariable stepwise regression analysis was performed using the expression results of CC of the 75 or 67 MII oocytes in order to develop a model predictive for each of the parameters considered for embryo competence. (C) CC from COCs which resulted in a clinical pregnancy (+COCs) or no pregnancy ( -COCs) were compared in the GnRH antagonist and rFSH and the GnRH agonist and HP-hMG-stimulated patients. (D) Using a multivariable stepwise regression analysis, the expression results of the CC of the 42 transferred embryos were used to develop a model predictive for pregnancy.
analyzed. From three patients out of each treatment, the three stages of oocyte maturation were available. The remaining patients had CC from either GV or MI oocytes combined with MII. Expression results from CC surrounding GV or MI oocytes are only used in the GV/MI/MII comparison.
RNA extraction and cDNA synthesis
Total RNA was extracted as described earlier . In brief, the extraction was performed using the RNeasy Micro Kit (Qiagen, Westburg, Leusden, The Netherlands) on the Qiacube (Qiagen) using the RNeasy DNase-digestion extraction protocol, where 5 ng/ml poly(dA) (Roche Applied Science, Mannheim, Germany) was added prior to extraction. After extraction, a second DNase treatment (RQ1 RNase-Free DNase, Promega, Leiden, The Netherlands) was performed according to the manufacturer's protocol in a 22-ml reaction volume. This RNA was diluted one on two at the end and stored at 2808C.
RT was performed on 40 ml RNA using the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Ghent, Belgium) according to the manufacturer's protocol with a reaction volume of 60 ml subsequently diluted to 100 ml. Two negative controls were generated by omitting the reversed transcriptase enzyme or the RNA in the RT reaction. All cDNA was stored at 2808C until PCR analysis.
Real-time PCR
Primers for SDC4, PTGS2, VCAN, ALCAM and GREM1 have been described earlier . Primers for TRPM7, CALM2 and ITPKA (Table II) were designed using the Universal Probe Library software (Roche Diagnostics, Roche Applied Science) and were chosen to be intron spanning. B2M and UBC were found to be stably expressed in human CC with the geNorm program (Vandesompele et al., 2002) after analyzing the expression of 13 primer pairs: ACTB, GAPDH, UBC, B2M, YWHAZ, SF3A1, 18S, CYC1, EIF4A2, SDHA, TOP1, ATP5B (PrimerDesign, Southampton, UK) and AluJ in 12 representative human CC samples (Supplementary data, Graph S1). The geometric mean of the B2M and UBC expression is considered as the endogenous normalization factor.
For GREM1 the Taqman gene expression assay Hs00171951_m1 was used (Applied Biosystems, Lennik, Belgium) on the LC480 (Roche Diagnostics, Roche Applied Science) following the manufacturer's instructions, adapted to 15 ml PCRs. All other genes were run on the LC480 in 15 ml reactions of LC480 SYBR Green I Master (Roche Diagnostics, Roche Applied Science) with 2 ml cDNA and 0.6 mM primer concentration for the genes of interest and 0.3 mM for the endogenous controls. Activation was done at 958C for 10 min. Cycling conditions were: 40 -50 cycles of 10 s at 958C and 30 s at 608C except for CALM2, where annealing was done at 638C. All samples were run in dupli-or triplicate and quantified using a standard curve generated by the log6 diluted synthetic oligonucleotide equal to the amplicon. On each plate, a no template control was included. To asses the specificity of amplification, a melting curve was carried out on all samples and sequenced once, except for GREM1. All negative controls were as expected, and all results mentioned later are the values normalized for the mean concentrations of B2M and UBC for this sample.
Expression correlations and betweenand within-patient expression variation
In order to explore the correlations within the multivariate data set made up of gene expressions, taking into account all expression values obtained in CC of all MII oocytes (10 antagonist/rFSH and 10 agonist/HP-hMG patients, all cultured in BlastAssist), a biplot was generated. The biplot is drawn along the first and second principal component, which together represent 51% of the total variability, with the points representing the individual COCs.
Between-and within-patient variations of the hierarchical model were calculated using a linear mixed model with patient as random factor, where the total variability consisted of a within-patient variability part and a between-patient variability part. The results are represented in Table IV .
Statistical analysis
In the first analysis, the CC of oocytes in a different maturation stage were compared (Fig. 1A) ; first by analysis of variance (ANOVA) and Tukey post-test considering all observations of these patients individually, and secondly by a paired t-test comparing the average per maturation class for each patient.
In a second analysis, a predictive model for embryo development was created (Fig. 1B) by stepwise multiple regression analysis on all expression results of all MII oocyte CC obtained from: 10 antagonist/rFSH-stimulated patients (n ¼ 75) and 10 agonist/HP-hMG-stimulated patients (n ¼ 67). For each treatment, a linear regression model (y ¼ a + bx + cz + ds + et + fu + gv + hw) was built with the outcome parameters (listed in an earlier section and Table III) were added and this was repeated until the addition did not further improve the model. Finally, a backward regression step was performed excluding non-essential variables from the equation. All steps were evaluated based on the type III P-values. A P-value of 0.3 was used as final criterion to keep variables in the model. In a third analysis, CC of oocytes resulting in a pregnancy (+COCs) or not ( -COCs) after SET were compared for each stimulation protocols (Fig. 1C) . The patient characteristics and the expression results in the pregnant and non-pregnant groups were compared using the two-tailed t-test. Two parameter analyses (ANOVA and t-tests) were performed using GraphPad Prism 4.01 (GraphPad Software, San Diego, CA, USA).
In a final analysis, the expression in CC surrounding, the oocytes giving rise to the embryos selected for transfer was tested to predict pregnancy (19+ and 23 -COCs; Fig. 1D ) by two stepwise multiple regression models. To allow the simultaneous analysis (and higher n), each variable was added together with its stimulation interaction term, which was a multiplication of the variable and a variable representing the difference between the two stimulations. In the first model, only gene expression values were added. Stepwise the genes with the best type III P-value were added as long as they improved the predictive power. In a second pregnancy prediction model, the most significant variable of three groups were added, i.e., an expression value (SDC4, PTGS2, VCAN, ALCAM, GREM1, TRPM7, CALM2 or ITPKA), a Day 3 morphologic characteristic (number of cells, degree of fragmentation or the embryo quality score) and a patient or cycle characteristic (patient age or BMI, serum FSH, LH, E 2 and progesterone on day of hCG, the days of stimulation or the ovarian response). For both models, a backward step was performed to exclude non-essential variables. Significance of the models and the main variables were obtained respectively, if P , 0.01 or if P , 0.05. Multiple regression statistics were performed using S + 7.0 for Linux (Tibco, Palo Alto, CA, USA).
Graphs representing the relations found in the statistical model
To suggest the direction of the correlation for a specific gene and to illustrate the predictive power of the model with its confidence intervals (CIs), a dot plot with the gene expression in the horizontal axis and the predicted probability of the quality parameter in the vertical axis was made. For each gene expression value, the corresponding predicted value of the generalized linear mixed model was fit, together with its 95% CI. A lowess smoother was drawn through the points making up the line connecting the predicted values and the boundaries of the CI.
Results
The patient population
The main patient characteristics were not different for the patients with a clinical pregnancy or not (Table III) . For the antagonist/ rFSH-stimulated patients, the slightly higher daily gonadotrophin dose in the pregnant patients would suggest that the pregnant patients were less responsive, which corresponds to the slightly lower ovarian response but this was not significant and is of limited relevance given, the low number of patients. In the antagonist/ rFSH-stimulated patients, the proportion of mature and fertilized oocytes was slightly different between pregnant and non-pregnant patients. This was not considered important as they are for both conditions in the high range and expression analysis was done on individual COC. For the agonist/HP-hMG-stimulated group, no differences in patient characteristics between pregnant and non-pregnant patients were observed.
CC gene expression and oocyte nuclear maturity
All samples analyzed contained a sufficient amount of RNA to detect the two endogenous controls and all specific genes were detected in the CC of individual COC of ICSI patients at the time of pick up after either treatment. One-way ANOVA analysis comparing CC from the three oocyte maturation stages indicated whether the expression in CC of oocytes in the MI stage was comparable to the expression observed in CC of GV or MII oocytes in either patient population (results not shown) and were grouped accordingly to allow a paired t-test analysis. Paired t-test between the averages per class for each patient indicated that in antagonist/rFSH-stimulated patients, TRPM7 and PTGS2 expression was significantly up-regulated and VCAN was significantly down-regulated in the CC surrounding MII oocytes compared with that of MI and GV oocytes (Fig. 2) . CC gene expression also showed a tendency for up-regulation in MII oocyte CC for ITPKA (2-fold increase, P ¼ 0.1816) and down-regulation for CALM2 of 1.3 (P ¼ 0.078, data not shown) and for GREM1 of 1.4 (P ¼ 0.1333).
In CC of MII oocytes of agonist/HP-hMG-stimulated patients, ITPKA and PTGS2 were significantly up-regulated and VCAN and GREM1 were significantly down-regulated (Fig. 2) . TRPM7 expression tended to be higher in MII oocyte CC compared with MI and GV oocyte CC (1.3 up, P ¼ 0.1889).
Expression correlations and betweenand within-patient expression variation
In order to explore the correlations within the multivariable data set, a biplot was generated (Fig. 3) . In the biplot, points represent individual COCs; the smaller the distance between two points, the more similar their gene expression pattern; the smaller the distance between arrows, the stronger the genes are correlated. Samples from either treatment grouped together. This indicates that the expression patterns or dynamics are different between the two stimulation treatments, as could be expected from earlier observations . ITPKA and TRPM7, VCAN and PTGS2, and SDC4 and GREM1 were, correlated and the three calcium-pathway-related genes (i.e. ITPKA, TRPM7 and CALM2) seemed to form a distinct group from the extracellular matrix or signaling-related genes.
Overall, both between-and within-patient variation was large for all genes except TRPM7 in antagonist/rFSH-stimulated patients (Table IV) . In both treatment groups, between-patient variation was largest for PTGS2, whereas it was the smallest or nearly unexisting for TRPM7. Overall, between-patient variation seemed slightly larger in the agonist/HP-hMG-stimulated patients. Within-patient variation was largest for PTGS2 and ITPKA in antagonist/rFSH and for PTGS2 and for VCAN in agonist/HP-hMG-stimulated patients. TRPM7 and CALM2 had the lowest within-patient variation in both treatments. ITPKA was among the lowest in the agonist/ HP-hMG-stimulated patients but had a high within-patient variation in the antagonist/rFSH group. Figure 2 Influence of the nuclear maturation stage of the oocyte on CC gene expression. ANOVA analysis indicated that average MI expression levels were comparable with either GV or MII expression levels. MI CC expression results were pooled accordingly with either GV or MII oocyte CC results. Subsequently, a paired t-test analysis was performed between the averages for each of the two remaining classes per patient. In the graphs, lines connect values from the same patient. Only the graphs for the genes with (close to) significant differences are represented here; * indicate statistical differences with *P , 0.05, **P , 0.01, ***P , 0.001.
Prediction of embryo development based on a CC expression profile at pick up
In antagonist/rFSH-stimulated patients, a significant relation (P , 0.01) with a CC expression profile was determined for six out of the seven embryo-development-related parameters ( Fig. 1B ;Tables V and VI). Each of the eight genes studied was retained in at least one model, and most models contained two to three genes. The prediction of a transferable embryo on Day 5 was borderline not significant (P ¼ 0.0146). SDC4 and TRPM7 were most often retained as informative genes (in three models). Serum FSH at the day of the hCG stimulus was the clinical variable that was most often retained (in five models). SDC4 always demonstrated a positive correlation, whereas FSH always demonstrated a negative correlation to good embryo development (Table V) . For the most interesting outcome parameters, i.e., the prediction of a cleavage-stage embryo or blastocyst with quality score ¼ 1 on respectively Day 3 and 5 in antagonist/ rFSH-stimulated patients, the graphs depicting the correlation are given in Fig. 4B -D . CIs for the models are also represented on these graphs and are narrow in areas with more observations. In agonist/HP-hMG-stimulated patients, only one had transfer on Day 5; so Day 5 models were not relevant. For four out of the five remaining embryo development-related parameters, a significant relation with a CC expression profile could be determined (Tables V and VI ). Only the model for prediction of fertilization was not significant (P . 0.01). Overall models for the agonist-stimulated patients contained less genes compared with the models for the antagonist-stimulated patient, i.e., four agonist patient models contain only one gene. CALM2, FSH and LH serum concentrations on day of hCG injection were most often retained. The strongest correlation in agonist/HP-hMG-stimulated patients was found for PTGS2 expression and probability on fertilization (Fig. 4A) .
The most striking similarities between models for the two treatment groups were: first, the similarity in the model predicting embryo quality 1 on Day 3, and second, the similar sense of correlation, being negative for VCAN and positive for CALM2 and ITPKA. The most striking differences are the fact that ALCAM and GREM1 seem less important in the agonist/HP-hMG-stimulated patients and the fact that the FSH level measured on day of hCG is inversely correlated in the two stimulation groups. Serum progesterone was not retained as an important correction factor for either treatment. Correlations with LH and FSH concentrations might be valid in the current set of patients but should be interpreted with care since they deal with only 10 data points (10 patients) while expression correlations result from many COCs ( Table V) .
Prediction of clinical pregnancy based on a CC expression profile at pick up CC of oocytes giving rise to successfully transferred embryos and pregnancy in antagonist/rFSH-stimulated patients had a higher expression of all genes ( Fig. 1C and D; Fig. 5 ; P , 0.05) but CALM2 (P ¼ 0.104). The mean expression increase varied from gene to gene and was 3-fold or more for SDC4, PTGS2 and ITPKA; between 2-and 3-fold for ALCAM, VCAN and GREM; and was 1.6-fold increased for TRPM7. In the agonist/HP-hMG-stimulated patients, there was no significant difference in gene expression for any of the studied genes between the CC of COCs resulting in a pregnancy or not (data not shown).
After the two variable analysis, a multivariate analysis was performed. This allowed the simultaneous analysis of samples from the two stimulation protocols in a stratified way (each variable was added together with its stimulation interaction term) and considered multiple variables at the same time. The prediction model for pregnancy (Fig. 1D ) using gene expression results as sole parameter contained the expression of SDC4 and VCAN (Tables V and VI) and had a P ¼ 0.0022. Extending with a third gene did not improve the significance. This model has a sensitivity of 74% (true positives/true positives + false negatives) and a specificity of 91% (true negative/ true negatives + false positives) in the current data set. A second pregnancy prediction model used gene expression values, embryo morphology, and patient and cycle characteristics. The expression values were the most significant variables (Type III P-values ,0.05 for all genes but CALM2 and ,0.005 for SDC4, VCAN, ITPKA); some patient and cycle characteristics were informative (Type III P-values ,0.05 for ovarian response), and embryo morphology was also of limited significance (the only variable with a type III P-values The multivariable data set is represented by the two principal components for the highest variability with the first and second principal component, respectively in the lower and left axes for plotting the arrows and the upper and right axes for plotting the individual points. Crosses represent the 75 CC of GnRH antagonist rFSH MII oocytes, and circles represent the 67 CC of GnRH agonist and HP-hMG MII samples. A biplot allows the display of the relationship between individual results (CC samples) and correlations among the variables (the different genes). Abbreviations of the genes are explained in Table II . The closer the sample markers, the more similar the gene expression pattern is for these CC samples according to the first two principal components. The closer the arrows to each other, the more the gene expressions are correlated. The differential grouping of the crosses and circles indicates both treatment groups display a different expression pattern. n ¼ total number (number positive for the criterium), Anta and Ago stand for GnRH antagonist and agonist respectively, rFSH, recombinant FSH, HP-hMG, higly purified human menopausal gonadotrophin, + or -indicate respectively positive or negative correlation, × the correlation is multifactorial and depends on the stimulation protocol. The embryo or blastocyst are scored 1-4 with 1 being the best score and a score of 2 often being the lower limit for transfer, # cells ¼ the number of cells of the embryo on Day 3. Significance of the models was obtained if P , 0.01. Gray boxes mark the variables with a type III P-value ,0.05.
,0.05 was number of cells on Day 3). The second pregnancy prediction model contained SDC4, number of cells on Day 3, ovarian response (Table VI) with a P , 0.0001, and a sensitivity of 78% and a specificity of 96%.
Discussion
CC gene expression analysis in ART patients is currently evaluated in several laboratories (McKenzie et al., 2004; Feuerstein et al., 2007; Assou et al., 2008; van Montfoort et al., 2008) . Five of the eight genes studied here (VCAN, SDC4, ALCAM, GREM1 and PTGS2) were confirmed to be expressed and regulated in mice CC during the final oocyte maturation (Adriaenssens et al., 2011) . A previous QPCR experiment on human CCs pooled per patient for the same five genes indicated also a between-patient variation for the selected genes . This variation could be related to patient and treatment-related variables, and to the gonadotrophin preparation used. Patient age was found to be positively correlated with the expression levels of half of the genes studied . Aiming to limit the influence of between-patient variation in the current (within-patient variation) study, inclusion criteria for age in the antagonist/rFSH-stimulated patients had been more stringent and resulted in a more homogenous population. However, still a considerable between-patient variation, mainly for PTGS2 and GREM1, exists (Table IV) . The remaining between-patient variation was compensated for, by the inclusion of patient and treatment variables in the prediction models. A large within-patient variation for quantitative expression values might be predictive for the discriminating power of a gene in the final analysis.
CC gene expression and nuclear maturity
There was no significant difference in expression of SDC4, ALCAM and CALM2 in the CC of either oocyte maturation stage for either treatment. PTGS2 expression was higher and VCAN expression was lower in CC of mature oocytes in the two stimulation groups. The higher expression of PTGS2 in CC of mature oocytes is in line with QPCR findings by others in GnRH agonist and rFSH-stimulated cycles (Feuerstein et al., 2007; Anderson et al., 2009 ). An earlier study suggested a negative correlation with nuclear maturity of VCAN in GnRH agonist and rFSH-stimulated patients and the absence of a correlation in agonist/HP-hMG-stimulated patients . VCAN expression differences in the current study are significant but less pronounced in the agonist/ HP-hMG-stimulated patients. The limited relation of GREM1 expression to the oocyte maturation in antagonist/rFSH-stimulated patients confirms findings of Anderson et al. (2009) in GnRH agonist cycles. The dynamics in CC gene expression in relation to the oocyte nuclear maturity thus seems to be consistent between studies and independent of stimulation protocols. Multiparametric analysis on QPCR data of cumulus genes is an original approach. It supports the idea of determining an optimal gene expression pattern as in microarray analysis (Assou et al., 2008) , but also allows the correction for patient-to-patient variance by including patient or cycle-specific variables. The stepwise regression analysis with type III P-value has the following advantages: (i) it allows the inclusion of multiple variables improving the prediction, (ii) it will not include correlating variables, (iii) it prevents the masking by possible patient-to-patient variation and (iv) allows the simultaneous analysis of two stimulation groups by using an interaction term (as was done for the pregnancy prediction model). While the inclusion of eight different genes and eight patient and treatment cycle variables was allowed, the most solid model retained most of the time only two (antagonist/rFSH-stimulated patients) or only one gene (agonist/ HP-hMG-stimulated patients) and maximally three correction factors (Table V) . In the models, the correction factors can compensate for the between-patient variation and the gene expression variables will account for the within-patient variation, e.g. the most competent oocyte or the ICSI outcome. This is the first study correlating CC gene expression with oocyte competence in GnRH antagonist cycles. Earlier studies from this laboratory indicated that stimulation with different gonadotrophin Figure 4 The predictive power and CIs for CC expression. To suggest the direction of the correlation and to illustrate the predictive power of the model, a dot plot with the gene expression in the X-axis and the predicted probability of the quality parameter on the y-axis is shown. The solid line represents the obtained linear regression model together with its 95% CI (dotted lines). Graphs A and B-D depict the most significant relations obtained for respectively the GnRH agonist and HP-hMG and the GnRH antagonist rFSH-stimulated patients. For the GnRH agonist and HP-hMG-stimulated patients, PTGS2 expression was positively related to the chance on fertilization (A) (P ¼ 0.049). For predicting an embryo quality 1 on Day 3, the influence of TRPM7 (C) (P ¼ 0.083) and ITPKA (B) (P ¼ 0.120) expression; and for blastocysts quality 1 on Day 5, the influence of SDC4 (D) (P ¼ 0.009) and ITPKA (P ¼ 0.056) (graph is quite similar to graph B) expression were most informative. To illustrate the use of the graphs (based on Fig. 4D ): for COCs with a CC expression of SDC4 below 6, the predicted chance on a top quality embryo on Day 5 is ,10% with a 95% CI ranging from 0 to 30%, (irrespective of the TRPM7 expression). COCs with a SDC4 expression higher than seven had on average a 70% chance on developing to a blastocyst with score 1 but with the 95% CI boundaries at + 20%. The expression is 2 -6 times higher in the subpopulation with the higher potential of growing to a score 1 blastocyst.
CC gene expression and oocyte competence preparations resulted in altered endocrine and cytokine environment in respectively human and mice (Smitz et al., 2007; Foster et al., 2010) and altered expression values or expression dynamics in the CC in a mouse and human (Adriaenssens et al., 2009 ). In the current study, the biplot also indicated a differential expression between the two stimulation protocols, which led to the development of individual predictive models for each stimulation protocol. The different models also confirmed specific differences after both stimulations. Since different embryo culture media can induce different cleavage kinetics and embryo morphology (Van Langendonckt et al., 2001) , only oocytes fertilized and grown in the same medium were considered for this analysis.
In the antagonist/rFSH-stimulated patients, each of the eight genes was retained/informative in at least one of the models for embryo development, and SDC4 and TRPM7 were the most important (Table V) . A strong correlation exists between SDC4 and the blastocyst score on Day 5. TRPM7 (P ¼ 0.083) was the most informative gene for selecting the best embryo (embryo score 1) on Day 3 of embryo culture.
In the agonist/HP-hMG-stimulated patients, CALM2 was most often retained and PTGS2 and VCAN had respectively a strong positive and negative predictive value (Table V) . The relation of TRPM7 CC gene expression with embryo/blastocyst morphology has not been stated earlier. The significance of SDC4 was suggested earlier by our group Figure 5 CC gene expression in COCs forming the transferred cleavage-stage embryo or blastocyst resulting in a pregnancy or not in GnRH antagonist and rFSH-stimulated patients. Dots represent the CC of the COCs selected for SET and resulting in a clinical pregnancy or not. * indicate statistical differences with *P , 0.05, **P , 0.01, ***P , 0.001, ns, not significant. in agonist/HP-hMG-stimulated patients , where SDC4 was found informative for the blastocyst development, a variable that was not available in the agonist/HP-hMG population in the current study. Other studies comparing CC gene expression based on prognostic factors such as embryo morphology on Day 3 found a higher expression of PTGS2 and GREM1 in agonist/hMG (McKenzie et al., 2004) and agonist/HP-hMG-stimulated cycles . In GnRH agonist/rFSH-stimulated cycles PTGS2 was negatively correlated to better embryo development (Feuerstein et al., 2007; Adriaenssens et al., 2010) . The current study indicates that PTGS2 is positively correlated to embryo morphology and score on Day 3 in antagonist/rFSH-stimulated patients and to fertilization in agonist/HP-hMG-stimulated patients. Extrapolating expression patterns or dynamics described in patients with different stimulation protocols should thus be done with great care.
One puzzling observation is that CC resulting in a pregnancy had a higher VCAN expression while VCAN expression was negatively correlated to good embryo or blastocyst morphology in both treatment groups. It is known that morphological scoring has a limited positive predictive value. Transfer of a single top quality embryo on Day 3 leads to an implantation in only one-third to one half of transfers (Ziebe et al. 2007) . Hence, optimal morphology is weakly associated with the chance of implantation or pregnancy. For the same gene, Van Montfoort et al. (2008) also described in the array results a 0.6-fold lower expression in CC of early cleaving embryos compared with those cleaving later, which is in line with our observations. Is CC gene expression useful to predict the most developmentally competent oocyte?
When trying to predict the best embryo or blastocyst based on the CC gene expression at pick up, the obtained models are quite strong. The graphs (Fig. 4A -D) depict the influence of the expression of one specific gene on the outcome parameter, taking into consideration also the values of the related variables. The CIs are still large for predictive values of 80%, but are narrowed down at the low end, where more data points were available. Therefore, prediction of suboptimal developmental competence can currently be done most accurately. SDC4 expression fits well in the model for quality prediction on Day 5 and has narrow CIs (Fig. 4D ). In the current patient population, COCs with a SDC4 expression lower than six have ,10% chance of developing into a blastocyst with score 1. COCs with 2-6 times higher SDC4 expression had on average a 70% chance of developing in to a high quality blastocyst.
CC collections are being prospectively undertaken to upgrade the current models by increasing numbers.
Is CC gene expression useful to predict pregnancy?
Only results from SET cycles were considered for this analysis. In the two stimulation groups, 50% of the transferred embryos led to a clinical pregnancy, of which 90% resulted in a live birth. The t-test revealed a significant expression difference for seven genes between the CC of oocytes, leading to a clinical pregnancy in the antagonist/rFSH-stimulated patients but found no significant differences in the slightly smaller sample set of agonist/HP-hMG-stimulated patients. In the current data set, the multivariate models, with two or three variables, and an interaction term (a nominator) for either stimulation group succeeded in predicting .70% of the + COCs leading to a pregnancy after transfer and .90% of the -COCs not leading to a pregnancy after transfer. Expression results were better pregnancy predictors than conventional embryo morphology scoring on Day 3. SDC4 and VCAN were the strongest predictive genes. The addition of the number of cells on Day 3 of embryo culture and the ovarian response variable to a model with only SDC4 improved the model, but the predictive power of this model was only marginally better than the model with only the expression of SDC4 and VCAN. Most of the currently selected genes are closely interrelated (Fig. 3) and might therefore provide only limited additional information. Genes related to different pathways might add more discriminating power. It needs to be emphasized that the pregnancy model did not stratify for the embryo culture medium and included the data from the two stimulation types that are quite different in expression level and dynamics. Further collections to increase the number of patients need to be performed to allow the validation of the current models in an independent data set and to eventually develop stimulation-specific pregnancy models.
Conclusions
ITPKA, CALM2 and TRPM7 are, for the first time, described in CCs. Immature or mature oocytes have distinct expression patterns in their surrounding CC. Mature oocytes had CC with increased PTGS2 and decreased VCAN expression.
In CC from mature oocytes, the selected genes had a considerable within-patient expression difference. This variation was significantly related to the morphological features observed during Day 3 and 5 embryo development. Apart from VCAN, all genes demonstrated a positive correlation with a better Day 3 or 5 morphology.
Overall, the patients stimulation protocol did not influence the expression pattern between CC of immature or mature oocytes. In the CC of mature MII oocytes, specific models were obtained for each stimulation protocol. In both groups, better cleavage-stage embryo prediction relied on TRPM7 and ITPKA expression, and the pregnancy prediction relied on SDC4 and VCAN expression.
The developed multivariate regression models for prediction of pregnancy had a sensitivity of .70% and a specificity of .90% in the current data set.
The current models could be used to select the oocyte with the highest chance of optimal blastocyst development and pregnancy.
Supplementary data
Supplementary data are available at http://humrep.oxfordjournals. org/.
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